Novartis' Jennifer Sheng on Solubility Modelling & the Future of Solubilisation

Add bookmark

Novartis' Jennifer Sheng on Solubility Modelling & the Future of Solubilisation

Add bookmark

Poor solubility is an obvious barrier to advancing potentially efficacious drug candidates. In this interview Jennifer Sheng, Fellow at Novartis, discusses the most efficient approaches for measuring solubility,  why solubility remains a critical challenge in formulation development and how solubility modelling can reduce the R&D timeline. 
[inlinead]

Have Your Say
Rate this feature and give us your feedback in the comments section below


Upcoming Events

DigIT Pharma 2026 | AI Commercial, Medical & Patient Care

September 9 - 10, 2026

Steigenberger Airport Hotel Berlin, Deutschland

DigIT Pharma 2026 | AI Commercial, Medical & Patient Care

Pharmaceutical Launch Excellence Summit US

September 30 - October 1 2026

Hyatt Regency Boston Harbor, Boston, US

Pharmaceutical Launch Excellence Summit US

SmartLab Exchange Europe

22 - 23 February 2027

Leonardo Royal Hotel Amsterdam, Netherlands

SmartLab Exchange Europe

Latest Webinars

Pharma IQ's Power List 2022: In conversation with pharma's top leaders

2022-10-18

02:00 PM - 03:00 PM BST

Join us to hear from the most influential people in pharma today, as voted for by you

A post-pandemic 3D view of the patient and supply journey

2022-06-01

04:30 PM - 05:30 PM CET

In this panel discussion with experts from 4G Clinical, THREAD Research and World Courier, learn how...

Discover how targeted radiotherapy induced toxicity can be identified with imaging

2022-04-28

01:00 PM - 02:00 PM EST

This Pharma IQ webinar with AIQ explores how AI-assisted analysis of radiological scans enhances the...

Recommended